Progressive Disease with Mixed Response After Immunotherapy in Non-Small Cell Lung Cancer
-
Published:2024-09
Issue:
Volume:Volume 17
Page:6317-6327
-
ISSN:1178-7031
-
Container-title:Journal of Inflammation Research
-
language:en
-
Short-container-title:JIR
Author:
Lv Juncai,
Yan Weiwei,
Zhang Ran,
Chen Xi,
Ren Ziyuan,
Chen DaweiORCID,
Yu JinmingORCID
Publisher
Informa UK Limited
Reference33 articles.
1. Colorectal cancer statistics, 2020
2. Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
3. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
4. Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
5. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial